A Phase Ib/II, Multicenter, Randomized, Single-Masked, Sham Injection-Controlled Study of Safety, Tolerability, and Evidence of Activity of FCFD4514S Intravitreal Injections Administered Monthly or Every Other Month to Patients With Geographic Atrophy

Trial Profile

A Phase Ib/II, Multicenter, Randomized, Single-Masked, Sham Injection-Controlled Study of Safety, Tolerability, and Evidence of Activity of FCFD4514S Intravitreal Injections Administered Monthly or Every Other Month to Patients With Geographic Atrophy

Completed
Phase of Trial: Phase I/II

Latest Information Update: 01 Nov 2016

At a glance

  • Drugs Lampalizumab (Primary)
  • Indications Dry age-related macular degeneration
  • Focus Therapeutic Use
  • Acronyms MAHALO
  • Sponsors Genentech
  • Most Recent Events

    • 04 Dec 2013 New trial record
    • 27 Aug 2013 Results were presented at the 31st Annual Meeting of the American Society of Retina Specialists in August 2013.
    • 27 Aug 2013 Primary endpoint 'Disease-progression' has been met.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top